Wright State University

CORE Scholar
Browse all Theses and Dissertations

Theses and Dissertations

2019

Effect of Endothelial Progenitor Cell-derived Exosomes on High
Glucose and Hypoxia/ Reoxygenation-induced Injury of Astrocytes
Manasi Suchit Halurkar
Wright State University

Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all
Part of the Pharmacology, Toxicology and Environmental Health Commons

Repository Citation
Halurkar, Manasi Suchit, "Effect of Endothelial Progenitor Cell-derived Exosomes on High Glucose and
Hypoxia/ Reoxygenation-induced Injury of Astrocytes" (2019). Browse all Theses and Dissertations. 2110.
https://corescholar.libraries.wright.edu/etd_all/2110

This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has
been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE
Scholar. For more information, please contact library-corescholar@wright.edu.

EFFECT OF ENDOTHELIAL PROGENITOR CELL-DERIVED EXOSOMES ON
HIGH GLUCOSE AND HYPOXIA/REOXYGENATION-INDUCED INJURY OF
ASTROCYTES

A thesis submitted in partial fulfilment of the
requirements for the degree of
Master of Science

by

MANASI SUCHIT HALURKAR
B. Pharm, University of Mumbai, India, 2015

2019
Wright State University

WRIGHT STATE UNIVERSITY
GRADUATE SCHOOL
1st JULY 2019
I HEREBY RECOMMEND THAT THE THESIS PREPARED UNDER MY
SUPERVISION BY Manasi Suchit Halurkar ENTITLED, Effect of endothelial progenitor
cell-derived exosomes on high glucose and hypoxia/reoxygenation-induced injury of
astrocytes. BE ACCEPTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
FOR THE DEGREE OF Master of Science.

Ji C. Bihl, M.D., Ph.D.
Thesis Director

Jeffrey B. Travers, M.D., Ph.D.
Chair, Department of
Pharmacology and Toxicology
Committee on Final Examination

Ji C. Bihl, M.D., Ph.D.

Yanfang Chen, M.D., Ph.D.

Adrian Corbett, Ph.D.

Barry Milligan, Ph.D.
Interim Dean of the Graduate School

ABSTRACT

Halurkar, Manasi Suchit. M.S. Department of Pharmacology and Toxicology, Wright
State University, 2019. Effect of endothelial progenitor cell-derived exosomes on high
glucose and hypoxia/reoxygenation-induced injury of astrocytes.

In this study, we tested the protective effects of EPC-EXs (endothelial progenitor cell
derived exosomes) and miR-126 EPC-EXs (microRNA-126 EPC-EXs) on the astrocytes
injured by HG (high glucose) plus H/R (hypoxia/reoxygenation) model. At first, we
determined the concentration and time dependent uptake of EPC-EXs by astrocytes. It was
also found that the EPC-EXs were uptaken via macropinocytosis, caveolin-dependent and
clathrin-mediated pathways in astrocytes. Furthermore, the astrocyte cell line was injured
through the HG + H/R model. EXs, isolated by ultracentrifugation from the EPC culture
supernatant were co-incubated with the injured cells. It was found that EPC-EXs and miR126 EPC-EXs decrease apoptosis, lipid peroxidation, oxidative stress and cytotoxicity in
the injured cells, hence protecting them.
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I. INTRODUCTION
1. Ischemic Stroke
1.1. Prevalence, definition and types
The third leading cause of death in the United States is stroke, killing around 140,000
people each year [1]. It leads to long-term serious disability, high frequency of recurrence,
reduction in mobility and other unfortunate consequences [2]. Stroke is a cerebrovascular
accident, also known as a brain attack, is defined as a global or acute neurological deficit
that is bound to last for more than 24 hours or leading to death [4]. It occurs when the blood
supply to the brain is interrupted unexpectedly, leading to the death of the brain cells which
are bereft of the nutrition and oxygen supplied by the blood [3]. It is broadly classified, on
the basis of its underlying pathological condition, into ischemic stroke and haemorrhagic
stroke and has no etiology other than the vascular origin. Ischemic stroke occurs when
blood vessel carrying blood to the brain is obstructed via a thrombus formation within or
an embolus, while the rupture of a blood vessel leads to haemorrhagic stroke [5]. However,
an acute stage of stroke which is known as the Transient Ischemic Attack (TIA) is defined
as a temporary event wherein the signs and symptoms of stroke resolve within 24 hours of
its occurrence [6].
Ischemic stroke accounts for 80% of the total stroke cases and is more prevalent with
growing age and changing lifestyle of people. It occurs when a cerebral artery, an artery
carrying blood to the brain, is blocked thus the blood supply is interrupted, resulting in
1

death of the brain cells due to lack of sufficient oxygen and nutrition [3]. The block could
either be a result of a thrombus formation, which can be a fat-based plaque or a blood clot,
within the blood vessel leading to thrombotic ischemic stroke or an embolus, which is a
free-formed clot formed elsewhere in the circulation but lodges itself into the cerebral
blood vessel thus leading to embolic ischemic stroke [7]. It can also be a result of stenosis
wherein the blood vessel narrows due to the fat deposition and clots along the vessel walls
[8].

Fig 1:Ischemic Stroke. The atherosclerotic
blood clot within the cerebral blood vessel
leading to hypoxic condition in the brain thus
cell death [9].

1.2. Risk factors
There are various underlying causes and risk factors associated with ischemic stroke. These
factors can be classified into modifiable and non-modifiable factors. The non-modifiable
risk factors, which tend to be the markers for higher risk of stroke, include age, sex, raceethnicity, heredity and geographical location. Incidence and risk of stroke occurrence
increases with increasing age, wherein after 55 years of age it doubles for every decade.
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Higher occurrence in women however more deaths due to stroke reported in men, a
possible reason being that the women outlive the men. Higher stroke occurrences found in
African Americans (2-4 folds), Hispanics (2 folds) and Chinese in comparison to nonHispanic Whites. Higher incidence in first-degree relatives by 2 folds [10].
The modifiable risk factors on the other hand are the reversible aspects which account for
the lower risk of stroke being amenable to intervention. These factors include various
conditions and diseases such as hypertension, atrial fibrillation, coronary heart diseases,
left ventricular hypertrophy, alcohol consumption, obesity, diabetes mellitus, smoking,
hyperlipidaemia and physical inactivity [3,10, 11, 12]. These conditions are responsible for
increased incidence of ischemic stroke and thus need to be taken care of medically in order
to avoid the stroke risk.

Non-Modifiable

Modifiable

Age
Gender
Race
Ethnicity
Previous stroke history

Hypertension
Diabetes Mellitus
Atrial Fibrillation
Cardiac disease
Smoking
Alcohol Consumption
Oral contraceptives
Hyperlipidaemia
Transient Ischemic Attack
Hormone therapy
Physical inactivity

Table 1: Risk factors associated with stroke.

1.3. Diagnosis and treatment
A series of diagnostic procedures are available to determine stroke development as well as
its location. Procedures such as computerized tomography (CT) scan gives a detailed image
3

of the brain focussing on the blood vessels in the neck and brain by the means of X-rays,
magnetic resonance imaging (MRI) employ magnetic and radio waves to detect tissue

Fig 2:Diagnostic tests for ischemic stroke in young adults. The figure is a graphical
representation of percentage of patients who underwent a certain test and the percentage which
depicted positive results for the same. CSF-Cerebrospinal fluid, CT-Computed Tomography, MRIMagnetic resonance imaging [15].

damage in the brain, carotid ultrasound shows the build-up of plaque and blood clot by
using sound waves and by cerebral angiogram wherein a dye is injected into a major blood
vessel and then imaged using X-rays for any block or clot inside the vessel [13,14].
Ischemic stroke is an expensive as well as a life-threatening disease costing around $40
billion to the US economy every year [16]. The primary motive of a therapy for this disease
is to either reverse or limit the complications, occurring after the onset, for the patient to
recover. The most standard mode of treatment employed for ischemic stroke is the use of
a thrombolytic agent, recombinant tissue plasminogen activator (rtPA) administered
intravenously (IV). This is the only approved therapeutic agent by the Food and Drug
Administration (FDA) for this disease condition till date. Although, only a few (3-5%) of
the stroke sufferers receive this treatment on time [17]. tPA is a serine protease by nature
which is converted into synthetic products by the means of recombinant technology thus
naming it as rtPA. Being a thrombolytic, it dissolves the clot by breaking the fibrin
4

molecules through the plasmin which is released from the activated plasminogen which is
fibrin-bound [18].

Fig 3: Mechanism of action of rtPA. rtPA binds to the fibrin mesh (formed by platelet aggregation
resulting in clot formation) thus activating the fibrin-bound plasminogen complex. This activation
leads to the release of plasmin from the complex which breaks up the clots by breaking up the
fibrin molecules thus inititating the process of fibrinolysis [18,19,20].

However, the treatment with rtPA is only viable for a small percentage of patients due to a
narrow therapeutic window of this drug, which lasts for upto 4.5 hours after the event onset.
Other therapies include the treatment via stem cell therapy, using various biomaterials and
mechanical thrombectomy as a part of endovascular intervention [21,22].

2. Diabetes Mellitus
2.1. Prevalence, definition and types
Diabetes mellitus, a chronic metabolic disorder associated with high blood glucose is one
of the major leading causes of death in the United States, reported as 7th in year 2015. As
per the guideline report presented by the International Diabetes Federation (IDF), the
number of people suffering from diabetes mellitus has been growing ever since [23,24].
The prime risk factors associated with the occurrence of this disorder are age, history of
diabetes, lifestyle, smoking, ethnic origin, obesity and improper diet. Although a higher
5

incidence of diabetes is observed in the population in the passing years, however around
30% of them are found to be undiagnosed cases. It is also a leading cause of various
complications such as cardiovascular and kidney diseases, retinopathy, limb amputations
and many such co-morbidities [25].
Diabetes mellitus is defined as a chronic disease or a metabolic syndrome wherein a rise in
blood glucose levels observed as a result of ineffective production of insulin by the
pancreas or the inability of body to respond to the insulin effectively. This increase in blood
glucose levels is responsible for damaging various body systems namely the blood vessels
and nerves [26]. Depending on its etiology, diabetes mellitus is classified into major two;
Type I Diabetes Mellitus and Type II Diabetes Mellitus. Type I is also known as insulindependent diabetes while type II is often known as insulin-independent diabetes. However,
there are other minorly classified types as well, such as gestational diabetes mellitus
(GDM) and other specific types of diabetes [27,28].

2.2. Type I Diabetes Mellitus
Type I diabetes mellitus, also known as insulin-dependent diabetes which accounts 5-10%
cases of diabetes, occurs due deficiency in insulin production thus leading to high blood
glucose levels or hyperglycemia. This deficiency in insulin production is usually due to
pancreatic β-cell destruction. It is broadly classified into immune-mediated diabetes and
idiopathic diabetes. The patients suffering from type I diabetes need to be put on insulin
therapy in order to maintain the normoglycemic (normal glucose) levels in the body
[28,29].

6

2.3. Type II Diabetes Mellitus
This is the more common type of diabetes, found in about 90-95% of the diabetic
population. Although more prevalent, it is the controllable and reversible type of disorder
also known as insulin-independent diabetes [30]. In type II diabetes, the body develops
insulin resistance wherein the cells do not respond to the signal by insulin to take up the
blood sugar. Thus, leading to increased blood glucose levels as the glucose remains in the
blood and not being used up by the cells. In the beginning when insulin resistance starts
developing, it is known as the pre-diabetic phase which later on turns to complete resistance
by all cells, leading to hyperglycemia and damage to other body systems eventually [31].
Obesity and physical inactivity are two of the few major causes of type II diabetes. This
disorder is however reversible, in comparison to that of type I diabetes. It can be reversed
by making changes to lifestyle, eating healthy, adequate exercise, intake of proper
medication and quitting smoking and alcoholism. If left untreated or uncontrolled, it may
lead to severe nerve damage, chronic kidney disease, stroke, wound healing problems,
cardiovascular disorders, eye disease, lower extremities amputation, bladder problems and
hindrance of sexual activity [32]. Type II diabetes mellitus is one of the leading causes for
occurrence of ischemic stroke, thus patients with an underlying condition of diabetes are
at higher risk for developing stroke.

7

a

b

c

Fig 4: Types of Diabetes Mellitus. a) Healthy condition:
Efficient uptake of the glucose circulating in blood by the
cell in response to the action of insulin on insulin receptor;
b) Type I diabetes mellitus: Inability of pancreas to
produce sufficient insulin, thus high blood glucose levels;
and c) Type II diabetes mellitus: Pancreas produce
sufficient amount of insulin but the cells are unable to
respond to it efficiently [33].

2.4. Gestational Diabetes Mellitus (GDM) and Other Specific Types
GDM generally develops in 2-5% of pregnant women where insulin resistance is observed
during pregnancy, which did not occur previously. Due to this insulin resistant and
hyperinsulinemia, pregnant women develop diabetes. Various factors responsible for this
insulin resistance are insulinase enzyme production, growth hormone alteration, cortisol
and human placental lactogen secretion along with the insulin imbalance due to estrogen
and progesterone [34].
Other specific types of diabetes mellitus, also known as secondary diabetes, mainly occur
due to infection, endocrinopathies, chemical/ drug-induced diabetes, exocrine pancreas
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disease, genetic defects in β-cell function and insulin resistance and other genetic
syndromes related to diabetes [35].
2.5. Developing stroke due to diabetes mellitus

Fig 5:Possible mechanisms leading to stroke due to diabetes. The various possible mechanisms
leading to stroke due to the occurrence of diabetes mellitus within an individual [36].

Diabetes mellitus is one of the major modifiable risk factors for ischemic stroke.
Individuals suffering from this syndrome are 1.5 times likely to be affected by stroke than
the ones who are not [37]. The resulting hyperglycemia due to diabetes are responsible for
causing fat deposits or blood clots within the blood vessels. Hyperglycaemic condition also
leads to hardening of arterial walls and reduction in their elasticity thus leading to
acceleration of atherosclerosis. Diabetes leads to impairment of Nitric Oxide (NO)
mediated vasodilation due to increase in the inactivation of NO or because of decreased
interaction between NO and the smooth muscles. This results in endothelial dysfunction
which is one major cause of the resulting stroke in diabetic individuals [36]. Development
9

of atherosclerosis further leading to stroke is also a result of increased systemic
inflammatory response predicted through the markers- adiponectin, C-reactive protein and
cytokines (TNF-α, IL-1 & IL-6) [36, 38]. Thus, diabetes mellitus resulting into an ischemic
stroke is at a higher risk because of these factors combined.
3. Endothelial Progenitor Cells (EPCs)
3.1. Origin and function
EPCs are referred to as the cell population which further mature into endothelial cells
(ECs), thus known as the precursors of ECs. EPCs mobilize, differentiate and proliferate
into mature ECs. Ashara et al. identified a hematopoietic population, which were CD34
and Flk1 positive mononuclear cells, having the potency to prompt vasculogenesis [39].
These are bone marrow-derived circulating cells originating in the blood of umbilical cord
and periphery which were initially isolated using magnetic microbeads. These cells were
termed to have the properties of embryonal angioblasts leading to neovascularization and
re-endothelialisation. Apart from these functions, EPCs are involved in wound healing,
angiogenesis, tissue regeneration as well as remodelling [40,41].

Fig 6: Endothelial Progenitor Cell Function. [42]
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3.2. Role of EPCs in Ischemic Stroke
Previous studies involving EPCs have suggested that EPCs play a major therapeutic role
in ischemic stroke.

Fig 7: Various roles of EPCs in treating stroke. [43]

4. Exosomes
4.1. Introduction to exosomes
Exosomes are 30-100 nm sized, phospholipid bilayer extracellular vesicles (EVs). These
vesicles, discovered around 30 years back, are formed within the cell and released in the
extracellular space by undergoing a series of steps. Exosomes are released in the
extracellular space by almost all cells, under normal physiological or stressful conditions
and are found in biological fluids such as blood, urine, saliva, CSF and semen [44].
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Fig 8: Exosomes. EXs released by Epstein–
Barr virus-transformed B cell under
Transmission Electron Microscopy [45].

At the time of initial discovery, these vesicles were thought to be cell debris, which were
responsible for disposal of unwanted cellular components from the cellular environment.
However, in recent years they have gained recognition in being responsible for intercellular
communication, carrying information from one cell to another [46].
4.2. Biogenesis and Composition

Fig 9: Exosome biogenesis. A brief insight into the EX biogenesis
within a cell and their release in the extracellular space [47].
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EXs generate within the early endosomes which are formed by inward budding of the
plasma membrane. Early endosomes then mature into late endosomes also known as
multivesicular endosomes (MVEs) containing the intraluminal vesicles (ILVs). The MVEs
then fuse with the plasma membrane releasing the contents, which is the ILVs, into the
extracellular space, then denoted as EXs [47, 48].

Fig 10:EX composition. EXs are composed of a varied collection of
biomolecules such as the mRNA, miRNA, DNA, proteins and lipids [49].

During the endosomal maturation stage, after which the MVEs are generated, cargo sorting
within the endosomes occurs. Cargo sorting is responsible for the overall contents of the
exosomes and hence their varied functions. This process is regulated by either Endosomal
Sorting Complex Required for Transport (ESCRT)-mediated pathway or ceramidedependent pathway. They are interchangeably known as non-ceramide pathway and nonESCRT dependent pathway respectively. The ESCRT-mediated pathway incorporates four
components, namely ESCRT-0, I, II and III, each of which are responsible for varied
13

functions in regard to the cargo sorting. While the ceramide-dependent pathway involves
lipid rafts which are glycolipoprotein microdomains. However, the cargo carried by these
EXs is a function of the parent cells within which these EXs are formed. The EXs are found
to mainly contain mRNA, miRNA, DNA, lipids and proteins [48, 49, 50].
4.3. Isolation
There are various methods of EX isolation discovered over the years, and each of these
methods have their own advantages and disadvantages on being looked for. Some of these
methods are differential centrifugation (more commonly known as ultracentrifugation),
density gradient centrifugation, filtration, size exclusion chromatography, polymer-based
precipitation, sieving and immunological separation. The most commonly and widely used
method, also known as the gold standard method of EX isolation, is the isolation by
ultracentrifugation. Ultracentrifugation involves centrifugation at high-speed in order to
obtain the EX pellet. It is the most commonly used method to derive EXs from biological
fluids [51].
4.4. Detection and Characterization
EXs, after isolation, can be analysed by various methods for determining their morphology,
quality, size and concentration. These methods are broadly classified into antibody-based,
optical and biophysical methods. Various EX specific antibodies and arrays are available
which are detected by FACS/flow cytometry or ELISA. The optical methods comprise of
Nanosight Tracking analysis (NTA) which works by the principle of detection of Brownian
motion of these particles under the laser; scattering flow cytometry (SFC), fluorescence
microscopy and dynamic light scattering (DLS). While the biophysical methods involve
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scanning electron microscopy (SEM), transmission electron microscopy (TEM) and atomic
force microscopy (AFM) [52,53].
4.5. EX uptake
Literature and studies have suggested that there is more than one pathway or mechanism
for the uptake of EXs by the cells. However, this uptake is a characteristic of the recipient
cell rather than the donor cell. In the recent years, more studies are being conducted to
know more about the uptake pathways and their unique characteristics. The uptake
pathways are broadly classified into membrane fusion and endocytosis. Major uptake is
carried out via the endocytic mechanism. Endocytosis is further classified into
phagocytosis, macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated
endocytosis, lipid-raft mediated endocytosis and receptor mediated endocytosis (67).

Fig 11:Pathways participating in EX uptake. [67]
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4.6. Function
Studies have suggested that EXs are involved in cellular signalling, wherein they carry
information in the form of biomolecules from the parent cell to the recipient cell. This
remains to be the unique function of EXs. Along with this, they are involved in facilitation
of immune response, angiogenesis, wound healing, inflammation and coagulation [54].
They are also considered to be biomarkers in diagnosis and prognosis of various medical
conditions and have proved to have immense diagnostic potential over the years. However,
the most important property of EXs, which has gained some limelight over time, is that
they can act as therapeutic agents and drug delivery carriers. The reason being the cargo
present in these vesicles which is then expelled into the recipient cell for its own benefits.
This cargo can then provide the required therapy. Although, the cargo either depends on
the parent cell or if it has been edited for specific drug delivery [55].
4.7. Studies on EPC-EXs
Various studies in the recent years have focussed on the therapeutic efficacy of EPC-EXs.
In year 2016, Li X. et al. determined that EPC-EXs are involved in vascular repair
attenuation and acceleration of reendothelialization [56]. While, Li X. et al. and Zhang J.
et al. proved that EPC-EXs accelerate cutaneous wound healing by promoting endothelial
function and promoting angiogenesis via Erk1/2 signalling respectively [57, 58]. In 2017,
Ke X. et al. found EPC-EXs responsible in increasing angiogenesis and proliferation in
cardiac fibroblasts [59]. While Jia Y. et al. in 2019 suggested that EPC-EXs are involved
in accelerating bone regeneration by regulating angiogenesis, in the distraction
osteogenesis phase [60].

16

5. MicroRNA-126
5.1. Definition and Location
MicroRNA-126 (miR-126) is an endothelial-specific miRNA found to be expressed in a
broad range of tissues, specifically the vascular system and highly vascularized tissues such
as lungs and heart.

Fig 12:miR-126 location. miR-126 located on chromosome 9 [61].

miR-126 is found on the human chromosome 9, located on the 7th intron of the epidermal
growth factor-like domain 7 (EGFL7) gene. miR-126 is expressed in its stem loop structure
with its complementary strand miR-126* [61].
5.2. Downstream Targets
Potential targets of miR-126 are vascular endothelial growth factor A (VEGF-A), vascular
cell adhesion molecule 1 (VCAM-1), insulin receptor substrate 1 (IRS-1), sprouty related
EVH1 domain containing 1 (SPRED-1) and PI3K (phosphoinositol-2-kinase) regulatory
subunit p85 beta (PIK3R2).
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5.3. Function
Like all other miRNAs, miR-126 also has specific functions. As miR-126 is endothelial
specific, its functions also rely on that property. Hence, miR-126 is predominantly involved
in angiogenesis and thus a prospective target for regulation of vascular integrity and
treating various vascular disorders [62,63]. Studies have proved that priming of this
miRNA in EPCs have been beneficial in enhancing their therapeutic efficacy in ischemic
cerebral impairment [64]. It also functions in suppressing tumor growth in colorectal cancer
through CXCR4 targeting, while being involved in rescuing cardiomyocytes efferocytosis
due to diabetes [65, 66]. Owing to their therapeutic potential, they are deemed to be
beneficial in stroke and diabetes related therapies.

18

II. HYPOTHESIS AND SPECIFIC AIMS
Hypothesis:
EPC-EXs could be uptaken by astrocytes and have protective effects on HG and H/Rinjured astrocytes.
Specific aims:
Aim 1) 1a: To determine EPC-EXs uptake pattern in astrocytes.
1b: To determine the uptake mechanisms of EPC-EXs in astrocytes.
Aim 2) To assess the protective effects of EPC-EXs on HG and H/R-injured astrocytes.
Aim 3) To determine if miR-126 EPC-EXs have enhanced protective effects on HG and
H/R-injured astrocytes.

19

III. EXPERIMENTAL DESIGN
Design for Aim 1a:
EPCs were cultured and allowed to be 80% confluent followed by serum starvation for 48
hours. The culture medium was collected for EX isolation. The obtained EPC-EXs were
fluorescent labelled with PKH26 and resuspended in astrocyte (ASC) medium.
Concentration-dependent uptake of the labelled EPC-EXs was determined by dividing the
EPC-EXs in 3 concentrations - 1 x 109 , 2 x 109 and 3 x 109 EX particles/ml, which were
added to the ASCs for 24 hours after which the cells were stained with DAPI and
fluorescent images were obtained. Time-based uptake was determined by adding the
labelled EPC-EXs to the ASC culture wherein the fluorescent images and flow cytometry
data was obtained at 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 hours.
Design for Aim 1b:
EPCs were cultured and allowed to be 80% confluent followed by serum starvation for 48
hours. The culture medium was collected for EX isolation. The obtained EPC-EXs were
fluorescent labelled with PKH67 and resuspended in astrocyte (ASC) medium. On the
other hand, the ASCs were cultured and grown till 80% confluency followed by treatment
with vehicle, 80 μM Dynasore, 10 μM Pitstop 2, 200 μM Genistein or 5 μM LY294002 for
30 minutes. The cells were then washed and the labelled EPC-EXs were added for 24 hours.
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The mechanism of uptake was determined by obtaining fluorescent images and performing
flow cytometry. ASCs at passages 4-10 and EPCs at passages 4-12 were used for this study.

Fig 13: Pictorial representation of Aim 1 experimental design.

Design for Aim 2:
EPCs were cultured and allowed to be 80% confluent followed by serum starvation for 48
hours. The culture medium was collected for EX isolation and the obtained EPC-EXs were
resuspended in ASC medium. ASCs were cultured and grown till 80% confluency,
followed by subjecting to 25 mM glucose for 24 hours. After this these culture plates were
put into the hypoxic chamber (with 1% O2, 5% CO2 and 94% N2) for 6 hours, followed by
reoxygenation for 24 hours. The isolated EPC-EXs were added to the cells during the
reoxygenation phase for the 24 hour period after which apoptosis, oxidative stress,
cytotoxicity and lipid peroxidation analysis were performed. ASCs at passages 4-10 and
EPCs at passages 4-12 were used for this study.
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Fig 14: Pictorial representation of Aim 2 experimental design.

Design for Aim 3:
EPCs were cultured and allowed to be 70-80% confluent, after which they were transfected
with miR-126 mimic using Dharmafect 1 transfection reagent, for 48 hours. Following the
trasfection, the cells were serum starved for 48 hours for EX release. The medium was
collected and miR-126 overexpressing EPC-EXs were isolated and resuspended in ASC
medium. ASCs were cultured and grown till 80% confluency, followed by subjecting to 25
mM glucose for 24 hours. After this these culture plates were put into the hypoxic chamber
(with 1% O2, 5% CO2 and 94% N2) for 6 hours, followed by reoxygenation for 24 hours.
The isolated EPC-EXs were added to the cells during the reoxygenation phase for the 24
hour period after which apoptosis, oxidative stress, cytotoxicity and lipid peroxidation
analysis were performed. ASCs at passages 4-10 and EPCs at passages 4-12 were used for
this study.
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Fig 15: Pictorial representation of Aim 3 experimental design.
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IV. MATERIALS AND METHODS
Materials
Human endothelial progenitor cells and human astrocytes were purchased from ATCC.
Human endothelial progenitor cell culture expansion media serum free with antibiotics and
human endothelial progenitor cell culture complete growth media with serum and
antibiotics were purchased from Celprogen (Torrance, CA). Astrocyte medium was
purchased from ScienCell (Carlsbad, CA). 0.05% trypsin-EDTA was purchased from
Gibco. PKH26, PKH67 and Dynasore hydrate were purchased from Sigma-aldrich (St.
Louis, MO). Dharmafect 1 from Dharmacon. miR-126 mimics were purchased from
Applied biosystems. (D)-glucose and pierce LDH cytotoxicity kit were purchased from
Fisher scientific. TRIzol reagent, dihydroethidium and Image-it lipid peroxidation kit were
purchased from Invitrogen (Carlsbad, CA). Annexin V and propidium iodide (PI) were
purchased from BDbiosciences. LY294002 was purchased from Enzo (Farmingdale, NY).
Genistein was purchased from EMD Millipore (Israel). Pitstop 2 was purchased from
Abcam (UK).
Cell culture
Human endothelial progenitor cells (HEPCs) and human astrocytes (ASCs) were used for
this study. HEPCs were cultured in HEPC complete growth medium with serum and
antibiotics in an incubator with standard cell culture conditions, that is 37°C and 5% CO2.
Culture medium was replaced every 2 days. EPCs at passages 4-12 were used for this study.
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ASCs were cultured in ASC medium with 10% fetal bovine serum (FBS), 5% ASC growth
factor and 5% penicillin/streptomycin (P/S) solution in a standard cell culture conditions
maintaining incubator. Culture medium was replaced every 3 days. ASCs at passaged 4-10
were used for this study. For passaging both these cell types, with 85-90% cell confluence
achieved, existing medium was replaced with 0.05% trypsin-EDTA at 37°C for 3 minutes,
then the respective medium with serum was added to stop the reaction. This was
centrifuged at 300 x g for 6 minutes, the pellet obtained was resuspended in respective
culture medium and passaged in 1:3 ratio for further culture.
EX isolation
EPCs were cultured in serum-free medium for 48 hours. After serum starvation, culture
medium was collected and centrifuged at 300 x g for 6 minutes, followed by 2000 x g for
20 minutes to remove the cells along with cell debris. The obtained supernatant was
centrifuged at 20,000 x g for 70 minutes, this allowed the pelleting of microvesicles (MVs).
As we do not make use of the MVs in our study, the obtained supernatant was subjected to
ultracentrifugation at 170,000 x g for 90 minutes to pellet the EXs [69]. After
ultracentrifugation, the supernatant was discarded, and the pellet was resuspended in 100
μl sterile-filtered phosphate buffer saline (PBS).
Nanoparticle tracking analysis (NTA)
The size and concentration determination of the isolated EPC-EXs was carried out by the
instrument NS300 (Nanosight, Amesbury, UK). NTA visualizes and measures particle size
and concentration by utilizing light scattering and Brownian motion properties. It can
detect size distribution of particles in solution from 10 nm to 2 μm in diameter. The
optimum particle concentration detected by NTA is ~107-109 particles/ ml. For better
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detection, the EX samples were diluted with sterile-filtered PBS to a concentration of 107108 particles / ml. After diluting the sample, 700 μl of the same was loaded in the instrument
for movement tracking at the rate of 30 frames/ second. The videos with particle movement
were recorded for at least 3 times per sample at different positions which were analysed by
the NTA software (version 2.2, Nanosight). The NTA results were produced as a mean of
the 3 tests performed per sample and the particle concentration was calculated after
considering the accurate dilution factor for the NTA results.
EX labelling
To label the EXs, PKH26 or PKH67, lipophilic-membrane dyes exhibiting red or green
fluorescence respectively, were used. The isolated EXs were added to a solution of 2 μl
dye in 1 ml PBS for 5 minutes. In order to stop the reaction, 1ml 1% BSA was added and
allowed to stand for a minute. This was then ultracentrifuged at 170,000 x g for 90 minutes,
to obtain the fluorescent (PKH26 or PKH67) labelled EX pellet. The supernatant was
discarded, and the pellet was resuspended in ASC medium for further co-incubation with
the cells.
Injury model for ASCs
The experimental model for this study was that of high glucose (HG) plus hypoxiareoxygenation (H/R) induced injury of ASCs, which is an in vitro representation of
ischemic stroke due to diabetes mellitus. For inducing the HG + H/R injury, the ASCs were
cultured in complete ASC medium until they were 80% confluent. Following this, the
ASCs were subjected to 25 mM glucose (in complete medium) for 24 hours after which
the cells were put into the hypoxia chamber, with 1% O2, 5% CO2 and 94% N2, for 6 hours.
Following this the ASCs were reoxygenated for 24 hours, at standard incubator conditions
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(37°C and 5% CO2), during which the EXs (unlabelled, EPC-derived or miR-126
overexpressed) were added.
Co-incubation of EXs with ASCs
The isolated EXs were resuspended in the ASC medium and added to the cells as per the
experimental design. The labelled, unlabelled, EPC-EXs or miR-126 overexpressing EPCEXs (miR-126 EPC-EXs) in concentrations 1 x 109, 2 x 109 or 3 x 109 EX particles/ml
were resuspended in complete ASC medium and then co-incubated with the ASCs for 24
hours. Following this, the fluorescent images were recorded, or assays were performed.
EX uptake mechanism determination
As the literature suggests, there are various pathways for EX uptake which predominantly
is based on the cell line being studied. To determine the EPC-EX uptake by ASCs, we
focussed on the endocytic uptake narrowing it down to macropinocytosis, clathrinmediated and caveolin-dependent pathways. For this, the cells were treated for 30 minutes
with various inhibitors at specific concentrations. The inhibitors used were 80 μM dynasore
(dynamin inhibitor), 5 μM LY290042 (macropinocytosis inhibitor), 10 μM pitstop 2
(clathrin inhibitor) and 200 μM genistein (caveolin inhibitor). After treatment with the
inhibitors, the cells were washed twice and then the labelled EPC-EXs were co-incubated
with these ASCs for 24 hours. Fluorescent images were obtained by fluorescence
microscope and flow cytometry analysis was carried out through Accuri C6 flow
cytometer.
miR-126 transfection
To generate miR-126 overexpressing EPC-EXs, the EPCs were transfected with miR-126
mimics (1 nm) using Dharmafect 1 transfection reagent for 48 hours in HEPC complete
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growth medium with serum and antibiotics followed by replacing the complete medium
with serum-free medium for 48 hours for release of EXs, isolated by ultracentrifugation at
170,000 x g for 90 minutes.
miR-126 expression analysis
miR-126 from the EPCs and EXs was extracted using the TRIzol reagent. After discarding
the culture medium from the flask, 1ml TRIzol reagent was added to the flask and made to
sit for a minute. This allowed the detachment of the cells, which were later transferred into
a 1.5 ml microfuge tube. To this, 100 μl chloroform was added and shaken for 15 seconds
until the solution turned pink. The tubes were allowed to stand for 10 minutes at room
temperature and then centrifuged at 12,500 x g for 15 minutes at 4°C. Centrifugation
resulted in separation of 3 layers, the topmost clear layer with the RNA extract, the middle
cloudy layer with the DNA interphase and the bottom most later with the cell debris. The
top clear layer was collected and transferred to a new tube to which 500 μl of pre-cooled
isopropanol was added, mixed thoroughly via pipetting and allowed to rest at -20°C for 10
minutes. Following this, the tubes were centrifuged for 12,500 x g for 15 minutes at 4°C,
and the supernatant was discarded. To the pellet, 1 ml of pre-cooled 75% ethanol was added
and vortexed. The tube was then centrifuged at 7500 x g for 5 minutes at 4°C and the
supernatant was discarded efficiently, after which the tube was dried in the ventilation hood
for 5-10 minutes. The obtained RNA was the eluted with 30 μl of RNase free water by
vigorous pipetting. The RNA concentration was measured using Nano drop 2000. cDNA
was synthesized using PrimeScript RT reagent kit (Takara Bio Inc.) following the
manufacturer’s instructions. qRT-PCR was carried out using miR-126 specific primers and
SYBR Premix Ex Taq kit (Takara Bio Inc.) on a real-time PCR instrument (Bio-Rad),
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while RNA U6 was used as an internal control for this determination. Expression of miR126 was calculated using 2−ΔΔCT method.
However, for the determination of miR-126 expression in the EXs, the similar steps were
carried out as the EPCs except for the initial few and the concentrations of reagents used.
After the isolation of EXs from the EPCs, the supernatant was discarded and to the tube
100 μl of TRIzol reagent was added. Following the same steps as before, 10 μl of
chloroform, 50 μl of isopropanol and 100 μl of 75% ethanol were used in their respective
steps. The RNA was eluted with 10 μl of RNase free water and the similar steps were
followed as the EPCs.
Cell apoptosis assay
Cellular apoptosis was determined using Annexin V/ PI. Annexin V is a potent biomarker
for cell apoptosis. It binds irreversibly to phosphatidyl serine, usually present on the inside
of the plasma membrane in normal conditions, which is exposed during apoptosis because
of scrambling of the plasma membrane. To determine apoptosis, ASCs were cultured in 6well plate, injured with the HG + H/R model and then treated with EPC-EXs. ASCs without
injury and EPC-EX treatment were treated as control. After this, the cells were detached
from the wells, transferred to microfuge tubes and centrifuged at 300 x g for 6 minutes to
obtain pellets. The pellets were resuspended in 100 μl of Annexin V binding buffer and
vortexed. To the isotype control, 5 μl of isotype PE and 5 μl of isotype APC were added
while to all the other groups 10 μl of conjugated PI and 5 μl of Annexin V were added. The
tubes were vortex again and allowed to sit for 15 minutes in dark, at room temperature.
The tubes were then centrifuged at 300 x g for 6 minutes, after which the supernatant was
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discarded, and the antibody-labelled cells were resuspended in 100 μl of Annexin V
binding buffer. The percent apoptosis was analysed using the flow cytometer.
Oxidative stress or intracellular ROS generation assay
Intracellular ROS generation, an effective method for determining oxidative stress in the
cells was determined using dihydroethidium (DHE) staining in this study. DHE is a
superoxide indicator which when oxidized primarily by a superoxide resulting in 2hydroxyethidium. This compound intercalates with the DNA and stains the nucleus bright
red, along with the cytosol. The ASCs were cultured in 6-well plate. After their
reoxygenation phase of the injury model, they were incubated with 10 μM DHE solution
(in dark) for 30 minutes at 37°C. The solution was then discarded, and the cells were
washed with PBS twice, and fresh new complete medium was added to the wells. ASCs
without injury and EX treatment were treated as control. The cells were then observed
under fluorescence microscope and the percentage of DHE-positive cells was analysed
using the flow cytometer.
Cell cytotoxicity assay
Cellular cytotoxicity determination is carried out using LDH cytotoxicity kit. This is a
steadfast colorimetric assay that measures cytosolic LDH (lactate dehydrogenase), an
oxidoreductase enzyme allowing the conversion of lactate to pyruvate, released into the
medium by injured (or damaged) cells. A series of enzymatic reactions involving the
released LDH result in generating a red fluorescent product, formazan. This resulting
formazan can be measured at 490 nm. To determine the cell cytotoxicity, ASCs were
cultured in 96-well plate (in triplicate wells), injured with the HG + H/R model and then
treated with EPC-EXs. ASCs without injury and EPC-EX treatment were treated as control.
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As per the manufacturer’s instructions, the triplicate wells for each group were categorised
into spontaneous LDH activity controls, maximum LDH activity controls and test LDH
activity. To the spontaneous LDH activity control wells, 10 μl of ultrapure water was added
and incubated at 37°C, 5% CO2 for 30 minutes. Following this, 10 μl of lysis buffer was
added to the maximum LDH activity control wells, mixed by gentle tapping and incubated
at 37°C, 5% CO2 for 45 minutes. After this, 50 μl of each sample medium was transferred
to a new 96-well plate, to which 50 μl of reaction mixture was added and incubated for 30
minutes at room temperature, in dark. To stop the reaction, 50 μl of stop solution was added
to each well and mixed by gentle tapping. Absorbance was measured at 490 nm and 680
nm and calculations for determination of percent cytotoxicity were carried out as per the
manufacturer’s instructions.
Lipid peroxidation assay
Lipid peroxidation refers to degradation of cellular lipids due to generation of reactive
oxygen species within the cell. For the determination of lipid peroxidation, a sensitive
fluorescent reporter BODIPY 581/591 C11 reagent (BODIPY dye) was used. The
phenylbutadiene portion of the dye allows the shift of fluorescence emission peak from
590 nm-red to 510 nm-green upon oxidation. To determine the lipid peroxidation, ASCs
were cultured in 6-well plate, injured with the HG + H/R model and then treated with EPCEXs. ASCs without injury and EPC-EX treatment were treated as control. Following this,
10 μM BODIPY reagent was added to the wells and incubated for 30 minutes at 37°C. The
media was removed followed by washing with PBS for 3 times. The ratio of reduction (590
nm)/oxidation (510 nm) was derived by reading the fluorescence intensities at the separate
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wavelengths on Cytation 5 plate reader while the percent lipid peroxidation was analysed
by the flow cytometer.
Statistical analysis
All data are expressed as mean ± SD of at least 3 experiments. Comparisons between two
groups were performed using Student’s t-test, while multiple comparisons were carried out
by one-way ANOVA, followed by Tukey’s post hoc test. A value of P < 0.05 was
considered statistically significant. All the statistical analyses were performed using
SigmaPlot (version 14.0) software.
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V. RESULTS

PKH26 labelled EPC-EXs were uptaken by ASCs in concentration and timedependent manner.
For the concentration-based study, cultured ASCs were co-incubated with PKH26 labelled
EPC-EXs at 3 different concentrations- EPC-EX 1: 1 x 109 particles/ml, EPC-EX 2: 2 x
109 particles/ml and EPC-EX 3: 3 x 109 particles/ml for 24 hours. The fluorescence images
were recorded after 24 hours indicating the labelled EPC-EX particles merged with the
ASCs. The intensity of the exhibited red fluorescence suggesting that the uptaking ability
of the EPC-EXs by the ASCs. The images suggested that the EPC-EXs were uptaken by
the cells in a concentration-based pattern, wherein the fluorescence exhibited increased as
the concentration of EPC-EXs increased (Fig 16A). However, for the time-dependent
study, PKH26 labelled EPC-EXs were co-incubated with the ASCs at a concentration of 3
x 109 particles/ml for 24 hours, wherein fluorescent images were recorded for every 2
hours. Again, the fluorescence intensity proved to be the basis for the uptaking of these
particles, merged with the cells. It was observed that the uptake was gradual as the time
passed, greater uptake and fluorescence intensity was observed at 16-18 hours. This
fluorescence gradually decreased until 24 hours suggesting the EXs being consumed by
the cells, hence the loss in fluorescence (Fig 16B). Fluorescence fold change was recorded
by flow cytometry at every time-point (Fig 16C).
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Fig 16: Concentration and time dependent uptake of EPC-EXs by ASCs. A)
Representative images of PKH26 (red) stained EPC-EXs merged with ASCs,
observed under the fluorescence microscope after 24 hours co-incubation. a-c1)
DAPI (blue) stained nucleus of ASCs, a2) 1 x 109 PKH26 labelled EPC-EX
particles/ml, b2) 2 x 109 PKH26 labelled EPC-EX particles/ml, c2) 3 x 109
PKH26 labelled EPC-EX particles/ml and a-c3) Overlay of images a with b. B)
Representative images of PKH26 stained EPC-EXs merged with ASCs at various
time points. C) Data summary representing fold change fluorescence for timebased uptake of PKH26 stained EPC-EXs by ASCs over 24 hours period.
Fluorescence images were obtained every 2 hours along with flow cytometry
data. Data represents mean ± SD, n = 3/ group.
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EPC-EXs were uptaken by ASCs via macropinocytosis, caveolin-dependent and
clathrin-mediated pathways.
To determine the uptake mechanisms, ASCs were treated with various synthetic drugs
which allowed the inhibition of the uptake of PKH67 labelled EPC-EXs. These drugs were
dynamin, macropinocytosis, clathrin and caveolin inhibitors. It was observed that the EPCEX uptake significantly decreased after the treatment of these inhibitors in comparison to
no treatment (Vehicle). ASCs were treated with vehicle (no treatment), 80 μM Dynasore
(dynamin inhibitor), 10 μM Pitstop 2 (clathrin-mediated pathway inhibitor), 200 μM
Genistein (caveolin-dependent pathway inhibitor) and 5 μM LY294002 (macropinocytosis
inhibitor) for 30 minutes. Fluorescent images were recorded after 24 hours co-incubation
(Fig 17A). The green fluorescence intensity suggested the uptake and merging of the EPCEXs with the cells. Decreased fluorescence suggested decreased uptake of the labelled
EPC-EXs by the cells hence, the inhibition of uptake had occurred after the drug activity.
Fluorescence fold change was recorded for each group by flow cytometry (Fig 17B).
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Fig 17: Mechanisms of uptake for EPC-EXs by ASCs. A) Representative
fluorescent images of PKH67 labelled EPC-EXs merged with ASCs after 30
minutes treatment by vehicle, 80 μM Dynasore, 10 μM Pitstop 2, 200 μM
Genistein and 5 μM LY294002, over an incubation period of 24 hours. B)
Fluorescence intensity fold change levels recorded by flow cytometric analysis.
Data represents mean ± SD, n = 4/group, *P (<0.05) v/s Vehicle, #P (<0.05) v/s
80 μM Dynasore, +P (<0.05) v/s 10 μM Pitstop 2.
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EPC-EXs decrease cellular apoptosis of HG + H/R injured ASCs.
To determine whether EPC-EXs could protect the ASCs from HG + H/R-induced injury,
we assessed the apoptotic rate of ASCs co-incubated with 2 concentrations of EPC-EXs.
The comparisons were based on the EPC-EX treatment provided to the ASCs after HG +
H/R-induced injury. The test groups were control (no injury or EPC-EX treatment), HG
(25 mM glucose), HG + H/R (injury without treatment), EPC-EX 1 (HG + H/R injured
ASCs treated with 1 x 109 EPC-EX particles/ml) and EPC-EX 3 (HG + H/R injured ASCs
treated with 3 x 109 EPC-EX particles/ml). Percent apoptosis determination was carried
out through flow cytometry, focussing on the Annexin V +/ PI – (early apoptosis phase) in
the quadrant 4 (Q4) (Fig 18A).It was found that the maximum concentration of EPC-EXs,
the EPC-EX 3 group, significantly decreased cell apoptosis after HG + H/R-induced injury,
thus protecting the cells against the injury (Fig 18B).
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Fig 18: Effect of EPC-EXs on HG + H/R-induced apoptosis of ASCs. A)
Representative flow cytometry plots for groups control, HG, HG + H/R, EPC-EX
1 and EPC-EX 3 with Annexin V on the y-axis and PI on the x-axis. B)
Summarized data showing percent apoptosis of ASCs after HG + H/R-induced
injury and EPC-EX treatment. EPC-EX 1: 1 x 109 EPC-EX particles/ml and EPCEX 3: 3 x 109 EPC-EX particles/ml. Data are represented as mean ± SD, n =
12/group, *P (<0.05) v/s Control, #P (<0.05) v/s HG + H/R. Groups: Control (no
injury or treatment), HG (High glucose), HG + H/R (High glucose +
hypoxia/reoxygenation),
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EPC-EXs decrease intracellular ROS generation due to HG + H/R-induced injury in
ASCs.
ROS generation is the key factor for injury in the cells due to increased oxidative stress
and intracellular lipid peroxidation. To deduce if EPC-EXs could protect the ASCs against
HG + H/R-induced injury by attenuating the oxidative stress and lipid peroxidation, DHE
and lipid peroxidation assays were carried out. ASCs were co-incubated with 2 different
concentrations of EXs (EPC-EX 1 with 1 x 109 EPC-EX particles/ml and EPC-EX 3 with
3 x 109 EPC-EX particles/ml) after the injury, while these groups were compared with HG
+ H/R injured ASCs group. ASCs without injury and treatment were treated as controls. It
was found that HG + H/R induced significant ROS generation and lipid peroxidation in the
ASCs, while the maximum concentration of EPC-EXs, EPC-EX 3 group, significantly
decreased the HG + H/R induced significant ROS generation and lipid peroxidation. Thus,
suggesting an important therapeutic of EPC-EXs in reversing the damage due to oxidative
stress and intracellular lipid peroxidation. DHE staining exhibited bright red fluorescence
(Fig 19A), detected by fluorescence microscope while the percent DHE-positive cells were
determined by flow cytometry (Fig 19B). To determine the intracellular lipid peroxidation,
ratio of reduction (590 nm)/oxidation (510 nm) was derived by reading the fluorescence
intensities (Fig 19C) while the percent lipid peroxidation was determined by flow
cytometry analysis (Fig 19D).
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Fig 19: Effect of EPC-EXs on oxidative stress and lipid peroxidation. A)
Representative DHE staining fluorescent images exhibiting bright red
fluorescence. B) Summarized flow cytometry analysis representing percent DHEpositive cells. C) Fluorescence intensity data summary representing ratio of
reduction (590 nm)/oxidation (510 nm). D) Summarized flow cytometry analysis
representing percent intracellular lipid peroxidation. EPC-EX 1: 1 x 109 EPC-EX
particles/ml, EPC-EX 3: 3 x 109 EPC-EX particles/ml. Data are represented as
mean ± SD, n = 6-10/group, *P (<0.05) v/s Control, #P (<0.05) v/s HG + H/R, +P
(<0.05) v/s HG, ^P (<0.05) v/s EPC-EX 1. Groups: Control (no injury or
treatment),
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EPC-EXs decrease cell cytotoxicity of HG + H/R injured ASCs.
To determine the protective effect of EPC-EXs on cell cytotoxicity levels, we assessed the
cell cytotoxicity for ASCs which were co-incubated with 2 different concentrations of
EPC-EXs (EPC-EX 1 with 1 x 109 EPC-EX particles/ml and EPC-EX 3 with 3 x 109 EPCEX particles/ml) after the injury, while these groups were compared with HG + H/R injured
ASCs group. ASCs without injury and treatment were treated as controls. The colorimetric
assay performed on these groups suggested that there is increased cytotoxicity due to the
HG + H/R injury, however EPC-EX 3 significantly decreases the percent cytotoxicity
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levels for the ASCs, thus protecting the cells from further damage. Percent cytotoxicity
was determined by the colorimetric LDH assay, reading the absorbance at 490 nm and 680
nm and performing the calculations as per the manufacturer’s instructions (Fig 20).
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Fig 20: Effect of EPC-EXs on cell cytotoxicity after HG + H/R injury of ASCs.
Summarized colorimetric absorbance readout data calculated to represent percent
cytotoxicity. EPC-EX 1: 1 x 109 EPC-EX particles/ml, EPC-EX 3: 3 x 109 EPCEX particles/ml. Data are represented as mean ± SD, n = 6/group, *P (<0.05) v/s
Control, #P (<0.05) v/s HG + H/R. Groups: Control (no injury or treatment), HG
(High glucose), HG + H/R (High glucose + hypoxia/reoxygenation), EPC-EX
(Endothelial progenitor cells-derived exosomes).
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Transfection of miR-126 mimics leads to overexpression of miR-126 in EPCs and
EPC-EXs.
In order to obtain miR-126 overexpressing EPC-EXs, EPCs were transfected and EPCEXs were isolated. The level of miR-126 in both cells and EXs were analysed by qRTPCR. The level of miR-126 in transfected EPCs was found to be almost 30 folds while that
for the isolated EPC-EXs was found to be around 5 folds (Fig 21).
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Fig 21: Effect of miR-126 mimic transfection on its expression. Summarized
data represents the fold change in levels of miR-126 expression in miR-126
transfected EPCs and isolated EPC-EXs in comparison to the untransfected
control. Data are represented as mean ± SD, n = 4/group, ***P (<0.05).
miR-126 EPC-EXs decrease cellular apoptosis of HG + H/R injured ASCs.
To determine the effect of miR-126 EPC-EXs on the apoptosis of HG + H/R injured ASCs,
Annexin V/ PI apoptosis assay was conducted. The comparisons were based on the EX
treatments provided to the ASCs after HG + H/R-induced injury. The test groups were
control (no injury or EPC-EX treatment), HG (25 mM glucose), HG + H/R (injury without
treatment), EPC-EX (HG + H/R injured ASCs treated with 3 x 109 EPC-EX particles/ml)
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and miR-126 EPC-EX (HG + H/R injured ASCs treated with 3 x 109 miR-126
overexpressing EPC-EX particles/ml). Percent apoptosis determination was carried out
through flow cytometry, focussing on the Annexin V +/ PI – (early apoptosis phase) in the
quadrant 4 (Q4) (Fig 22A). It was found that miR-126 EPC-EXs significantly decrease the
ASC apoptotic rate, however the results were not significant in comparison to the EPC-EX
group (Fig 22B).
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Fig 22: Effect of miR-126 EPC-EXs on HG + H/R-induced apoptosis of
ASCs. A) Representative flow cytometry plots for groups control, HG, HG +
H/R, EPC-EX and miR-126 EPC-EX with Annexin V on the y-axis and PI on the
x-axis. B) Summarized data showing percent apoptosis of ASCs after HG + H/Rinduced injury and EPC-EX treatment. EPC-EX: 3 x 109 EPC-EX particles/ml
and miR-126 EPC-EX: 3 x 109 miR-126 overexpressing EPC-EX particles/ml.
Data are represented as mean ± SD, n = 6/group, *P (<0.05) v/s Control, #P
(<0.05) v/s HG + H/R. Groups: Control (no injury or treatment), HG (High
glucose), HG + H/R (High glucose + hypoxia/reoxygenation), EPC-EX
(Endothelial progenitor cells-derived exosomes), miR-126 EPC-EX (microRNA
126 overexpressing EPC-EX).
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miR-126 EPC-EXs decrease HG + H/R induced intracellular ROS generation in
ASCs.
As discussed previously, ROS generation is a key factor in cell damage and death. To
determine if miR-126 EPC-EXs have an effect on the ROS generation, thus affecting the
oxidative stress and lipid peroxidation, DHE and lipid peroxidation assays were performed.
It was found that miR-126 EPC-EXs decrease the ROS generation significantly, however
there was no significant difference observed between the effects of groups EPC-EXs and
miR-126 EPC-EXs. DHE staining exhibited bright red fluorescence (Fig 23A), detected by
fluorescence microscope while the percent DHE-positive cells were determined by flow
cytometry (Fig 23B). To determine the intracellular lipid peroxidation, ratio of reduction
(590 nm)/oxidation (510 nm) was derived by reading the fluorescence intensities (Fig 23C)
while the percent lipid peroxidation was determined by flow cytometry analysis (Fig 23D).
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Fig 23: Effect of miR-126 EPC-EXs on oxidative stress and lipid peroxidation.
A) Representative DHE staining fluorescent images exhibiting bright red fluorescence. B)
Summarized flow cytometry analysis representing percent DHE-positive cells. C)
Fluorescence intensity data summary representing ratio of reduction (590 nm)/oxidation
(510 nm). D) Summarized flow cytometry analysis representing percent intracellular lipid
peroxidation. EPC-EX: 3 x 109 EPC-EX particles/ml, miR-126 EPC-EX: 3 x 109 miR-126
overexpressing EPC-EX particles/ml. Data are represented as mean ± SD, n = 6-10/group,
*P (<0.05) v/s Control, #P (<0.05) v/s HG + H/R. Groups: Control (no injury or treatment),
HG (High glucose), HG + H/R (High glucose + hypoxia/reoxygenation), EPC-EX
(Endothelial progenitor cells-derived exosomes), miR-126 EPC-EX (microRNA 126
overexpressing EPC-EX).
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miR-126 EPC-EXs decrease cell cytotoxicity of HG + H/R injured ASCs in
comparison to EPC-EXs.
To deduce the effect of the overexpressed miR-126 in the miR-126 EPC-EXs on cellular
cytotoxicity, we assessed the cell cytotoxicity for ASCs co-incubated with miR-126 EPCEXs (3 x 109 particles/ml) after the injury, while these groups were compared with HG +
H/R injured ASCs group as well as the EPC-EX treated injured group. ASCs without injury
and treatment were treated as controls. The colorimetric assay performed on these groups
suggested that there is increased cytotoxicity due to the HG + H/R injury, however miR126 EPC-EX significantly decreases the percent cytotoxicity levels for the ASCs, thus
protecting the cells from further damage. The interesting observation here was the data
showing significant difference in reduction of cytotoxicity in miR-126 EPC-EX and EPCEX groups, suggesting the enhanced effect of miR-126 EPC-EXs on the damaged cells.
Percent cytotoxicity was determined by the colorimetric LDH assay, reading the
absorbance at 490 nm and 680 nm and performing the calculations as per the
manufacturer’s instructions (Fig 24).
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Fig 24: Effect of miR-126 EPC-EXs on cell cytotoxicity after HG + H/R
injury of ASCs. Summarized colorimetric absorbance readout data calculated
to represent percent cytotoxicity. EPC-EX: 3 x 109 EPC-EX particles/ml, miR126 EPC-EX: 3 x 109 miR-126 overexpressing EPC-EX particles/ml. Data are
represented as mean ± SD, n = 5/group, *P (<0.05) v/s Control, #P (<0.05) v/s
HG + H/R, +P (<0.05) v/s miR-126 EPC-EX. Groups: Control (no injury or
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VI. DISCUSSION
EXs are nanosized, extracellular vesicles released by almost all cells in physiological as
well as stressful conditions. These phospholipid bilayer vesicles, generated within the
endosomes of the cells and released into the extracellular space via fusion with the plasma
membrane, are involved in cell-to-cell signalling and found to contain DNA, RNA, mRNA,
miRNA, lipds and proteins, which are responsible for the transfer of information. This
property of EXs exemplifies them as novel therapeutic agents also, qualifying them for
being involved in drug delivery. In this study we isolated the EXs from EPCs which were
uptaken by the ASCs via macropinocytosis, clathrin-mediated endocytosis and caveolindependent endocytosis mechanisms (Fig 17). Also, the uptake was increased with
increased time of co-incubation and concentration of EPC-EXs, thus highest uptake was
observed at the concentration of 3 x 109 particles/ml (Fig 16A) at 16-18 hours (Fig 16B,
16C), after which the levels decreased suggesting the consumption of these EPC-EXs by
the cells. These results suggest that EPC-EXs are effectively taken up by the cells in a
concentration and time-dependent pattern by 3 different uptake mechanisms (Fig 16, 17)
The in-vitro representation of ischemic stroke due to diabetes was achieved through HG +
H/R induced injury of ASCs. 25 mM glucose enriched medium correlates with the
physiological condition of diabetes while hypoxia, 1% O2, 5% CO2, 94% N2, for 6 hours
followed by 24 hours or reoxygenation at standard incubator conditions depicts the
physiological condition of ischemic stroke. H/R-induced injury lead to an increase in the
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ROS, apoptosis, while it decreased NO and eNOS production in the hb-ECs. However, the
EPC derived microvesicles (MVs) when co-incubated with the H/R damaged ECs, it
resulted in increased eNOS, NO production while rescuing the cells from ROS
overproduction and apoptosis [68]. Similar results were obtained in our study, however we
wanted to test the effect of EPC-EXs on HG + H/R injured ASCs. HG + H/R injury
induction resulted in early apoptosis of a population of cells which decreased when
treatment with 1 x 109 EPC-EX particles/ml was carried out. The population further
decreased with a treatment of higher concentration, that is 3 x 109 EPC-EX particles/ml
(Fig 18A). Further summarized data suggested that EPC-EXs at a concentration of 3 x 109
EPC-EX particles/ml, significantly decrease the apoptosis rate of ASCs (Fig 18B). These
results suggest that EPC-EXs protect the HG + H/R injured ASCs from apoptosis and help
them recover (Fig 18). ROS is one of the major players’ responsible for cell damage and
death after HG + H/R. In our study, we found that 3 x 109 EPC-EX particles/ml
significantly decreased the ROS generation represented by the bright red fluorescence and
the DHE-positive cells, however the lower concentration of EPC-EXs could not reduce the
ROS generation that significantly (Fig 19A, 19B). EPC-EXs were also found to decrease
the ratio of reduction/oxidation of intracellular lipids and lipid peroxidation within the
ASCs injured by HG + H/R. The colorimetric results suggested that EPC-EXs with the
concentration 3 x 109 EPC-EX particles/ml decreased the ratio which was elevated due to
HG + H/R injury (Fig 19C). While, the flow cytometry results proposed the increase in
lipid peroxidation after the injury which was significantly decreased by the EPC-EXs.
EPC-EX concentration of 1 x 109 EPC-EX particles/ml decreased the lipid peroxidation by
almost 30% while, 3 x 109 EPC-EX particles/ml reduced the lipid peroxidation by almost
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40% which was significantly different to the lower concentration of EPC-EXs used (Fig
19D). These results demonstrate the therapeutic efficacy of EPC-EXs in attenuating the
ROS generation by HG + H/R-induced injury (Fig 19). Cell cytotoxicity was another
parameter which was tested in our study involving the ASCs and the EPC-EXs. We found
a decrease in cell cytotoxicity after the treatment of injured ASCs with that EPC-EXs,
however only the EPC-EX concentration of 3 x 109 EPC-EX particles/ml significantly
reduced the cytotoxicity (Fig 20).
As mentioned previously, EXs are composed of biomolecules such as DNA, RNA, lipid
proteins, miRNA are short non-coding RNAs. miR-126 is a highly expressed endothelial
specific miRNA, located on the human chromosome 9. It has been noted that miR-126 has
proved to therapeutically efficacious in cerebral impairment due to ischemia [64]. miR-126
is endogenously expressed in EXs. In our study, as we are focussing on EPC-EXs as
therapeutic agents, we overexpressed the levels of miR-126 in both the cells as well as the
EXs derived from these cells. The results from this study showed ~30-fold increase in miR126 levels in the transfected cells when compared to the controls, while a ~5-fold increase
was observed in the EPC-EXs derived from the transfected cells to that of the control (Fig
21). This indicates that the miR-126 is effectively transfected and overexpressed in the
EPC-EXs which could in turn provide therapeutic efficacy.
miR-126 regulates several functions mainly being involved in angiogenesis, cell survival
and maintenance of vascular structure. Hence, it has proven to be beneficial in treating
various vascular diseases. It plays a vital part in recovery after ischemia-reperfusion injury.
miR-126 directly targets vascular endothelial growth factor A (VEGF-A), vascular cell
adhesion molecule 1 (VCAM-1), insulin receptor substrate 1 (IRS-1), sprouty related
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EVH1 domain containing 1 (SPRED-1) and PI3K (phosphoinositol-2-kinase) regulatory
subunit p85 beta (PIK3R2). In our study, we determined the effect of miR-126
overexpressing EPC-EXs on HG + H/R injured astrocytes. The data demonstrated a
decrease in ASC apoptosis after treatment with miR-126 EPC-EXs at a concentration of 3
x 109 miR-126 overexpressing EPC-EX particles/ml. However, the decrease due to miR126 was not significantly different from the effect of EPC-EXs on injured ASCs (Fig 22A,
22B). This suggested that miR-126 EPC-EXs also exhibit a protective effect towards HG
+ H/R injured ASCs. Similarly, miR-126 EPC-EXs, at a concentration of 3 x 109 miR-126
overexpressing EPC-EX particles/ml, significantly reduced the ROS generation elucidated
by the bright red DHE-stained cells (Fig 23A) as well as the summarized flow cytometry
data (Fig 23B). Again, the effect of miR-126 EPC-EXs was significant in comparison to
the injured group but not to the EPC-EXs group. This data proclaims that the miR-126
EPC-EXs are responsible for protecting the ASCs against oxidative stress. While, the lipid
peroxidation and cell cytotoxicity results showed a significant difference in the effect of
EPC-EXs on HG + H/R injured ASCs, by reduction in the reduced/oxidized ratio (Fig
23C), lipid peroxidation (Fig 23D) and cell cytotoxicity (Fig 24). However, the interesting
part was miR-126 EPC-EXs, at a concentration of 3 x 109 miR-126 overexpressing EPCEX particles/ml, significantly decreased the lipid peroxidation and cell cytotoxicity in
comparison to EPC-EXs at the same concentration. This intriguing data suggested that the
enhanced protective effects of miR-126 EPC-EXs, in comparison to EPC-EXs, may be due
to the overexpressing miR-126.
Through the entire study, it was proved that EPC-EXs do project a protective effect on HG
+ H/R injured ASCs. However, the enhanced effects due to miR-126 EPC-EXs remain
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unclear as an inhibitor of miR-126 was not employed here in order to determine the
enhanced effect exerted was solely due to miR-126 or there were other factors responsible
for the same. This would be an interesting part to investigate ahead in this study, along
with the determination of the potential targets for miR-126 in the ASCs.
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VII. CONCLUSIONS
Our data for this study demonstrates that the EPC-EXs are efficiently uptaken by the ASCs
in a time and concentration dependent manner. The major pathways for mechanism of
EPC-EX uptake in ASCs are macropinocytosis, clathrin-mediated endocytosis and
caveolin-dependent endocytosis. HG + H/R-induced injury to the ASCs lead to an increase
in apoptosis, oxidative stress, lipid peroxidation and cell cytotoxicity. However, the
treatment of EPC-EXs resulted in reduced apoptosis, oxidative stress, lipid peroxidation
and cytotoxicity thus, suggesting that EPC-EXs protect the ASCs from HG + H/R-induced
injury. The data also suggested that EPCs transfected with miR-126 mimics release miR126 overexpressing EPC-EXs. Treatment of injured ASCs with miR-126 EPC-EXs also
resulted in reduction of apoptosis, oxidative stress, lipid peroxidation and cytotoxicity
suggesting the protective effect of miR-126 EPC-EXs on HG + H/R injured ASCs.
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